Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Rhea-AI Summary

Cyclerion Therapeutics (Nasdaq: CYCN) announces that COO Cheryl Gault will present a corporate overview at B. Riley’s Neuroscience Investor Conference on April 29, 2021, at 1:00 p.m. ET. Attendees can also engage in one-on-one meetings with Cyclerion leaders at the event. The live webcast will be available on the Cyclerion website, along with an archived replay for 90 days. The company is focused on developing treatments to restore cognitive function, with its lead molecule, CY6463, currently in clinical development for Alzheimer's Disease with Vascular pathology and MELAS.

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley’s Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.   Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar.   An archived replay of the event will be available on the site for approximately 90 days following the presentation.

About Cyclerion Therapeutics 
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

FAQ

When will Cyclerion present at the B. Riley Neuroscience Investor Conference?

Cyclerion Therapeutics will present at the B. Riley Neuroscience Investor Conference on April 29, 2021, at 1:00 p.m. ET.

What is CY6463 and what diseases is it targeting?

CY6463 is Cyclerion's lead molecule, a CNS-penetrant sGC stimulator targeting diseases such as Alzheimer's Disease with Vascular pathology and Mitochondrial Encephalomyopathy.

How can investors access the Cyclerion presentation?

Investors can access the live webcast of Cyclerion's presentation via the Investors & Media section on their website.

What is the main mission of Cyclerion Therapeutics?

Cyclerion Therapeutics is focused on developing treatments that restore cognitive function.

Will there be opportunities for one-on-one meetings at the conference?

Yes, Cyclerion leaders will be available for one-on-one meetings during the B. Riley Neuroscience Investor Conference.